600161 Beijing Tiantan Biological Products Corporation
- 21.06
- -0.43-2.00%
Beijing Tiantan Biological Products Corporation News
Tiantan Biotech (600161): Performance fluctuations in the third quarter did not hinder full-year performance targets
Tiantan Biology (600161): Improving Profitability and Expanding Licenses to Help Open Up “Pulp” Sources
Tiantan Biotech (600161): The company's profit was stable in Q3 in 2024, and the merger and acquisition was extended to the next city
Tiantan Biotech (600161): Net interest rate continues to rise in 24Q3, and long-term growth can be expected
Tiantan Biotech (600161) First Coverage Report: A Growth Model for Central Enterprises Developing High Quality Blood Products
Tiantan Biotech (600161): Rapid profit growth in 24H1 plans to acquire Zhongyuan Reed to further enhance its comprehensive strength
Tiantan Biology (600161): The leading rapid release blood products of Jingpropylene is expected to grow steadily in the future
Tiantan Biology (600161): Pharmaceutical/essential consumption recovered strongly in the second quarter, and full year results can be expected
Tiantan Biology (600161): Rapid profit growth, steady progress in slurry source expansion
Tiantan Biology (600161): Leading blood products industry leader in chromatography is expected to release hydrochloric acid
Tiantan Biology (600161): Leading central enterprises in blood products are empowered to continue to expand high-purity isopropyl and recombinant eight factors to create new growth poles
Tiantan Biology (600161): Leading blood products companies are optimistic about long-term investment value
Tiantan Biotech (600161) Company Information Update Report: Performance for the first half of 2024 exceeded expectations and profitability continued to improve
Tiantan Biotech (600161): Sales recovered month-on-month, profit margins increased significantly
Tiantan Biology (600161): Performance exceeds expectations, leading blood products have plenty of room for a long time
Tiantan Biotech (600161) 2024Q1: Steady revenue and increased profitability
Tiantan Biology (600161): Central enterprise's leading blood products plasma station approved, strong research and release bureau to consolidate long-term competitiveness
Tiantan Biology (600161): Leading blood products, the number of pulp collection stations increased dramatically during the 14th Five-Year Plan period
Tiantan Biology (600161): Improving pulp harvesting and achieving remarkable results in R&D innovation, setting business goals, demonstrating confidence in development
Tiantan Biology (600161): The 24-year performance target shows the company's development confidence and firm optimism about the blood products market
No Data
